Prescription Drugs & Pricing
Expert articles and analysis related to prescription drugs & pricing.
AI Summary â Last 7 Days
Synthesis:
In the past week, CMS finalized the 2027 Medicare Advantage and Part D rule, introducing requirements that will reshape payment and access dynamics in both Medicare Advantage and the Part D prescription drug benefit, with key implications for plan sponsors and providers operating under value-based arrangements (summary). Additionally, CMS delayed the Part D component of the BALANCE Model for GLP-1 medications, signaling ongoing tensions between efforts to expand innovativeâand often costlyâdrug access and the need to balance budget impact and adherence incentives within value-based frameworks (details.
Related Articles
International Lessons on Pricing and Financing High-Cost Medicines: Policy Options for the United States
International Lessons on Pricing and Financing High-Cost Medicines: Policy Options for the United States  Commonwealth Fund
Beyond âMost Favored Nationâ Drug Pricing: What the U.S. Can Learn from Other Countries
Beyond âMost Favored Nationâ Drug Pricing: What the U.S. Can Learn from Other Countries  Commonwealth Fund
US reveals new Medicare prices for second round of IRA drugs
From newsletter: The LI Daily: GoodRx launches direct-to-employer platform aimed at lowering drug costs; 15 more high-profile drugs for IRA price negotiations GoodRx launches direct-to-employer plat...
Explaining the Prescription Drug Provisions in the Inflation Reduction Act | KFF
From newsletter: The LI Daily: GoodRx launches direct-to-employer platform aimed at lowering drug costs; 15 more high-profile drugs for IRA price negotiations GoodRx launches direct-to-employer plat...
The $500,000 drug and the cost of modern medicine
I met him as a patient with a back condition, not a cardiac patient. A 70-year-old man who looked like he had outrun aging through sheer willpower and a well-worn bicycle. He rode more than a hundred ...
Blue Shield of California taps chief pharmacy officer
Hayley Park will oversee BSCAâs prescription drug programs. The insurer has worked to overhaul its pharmacy management model in a bid to lower drug costs.
STAT+: The PBMs fight back, and arbitration doesnât lose
We unpack the contentious fight over drug price transparency.
STAT+: PBMs warn Trumpâs proposal to disclose drug prices is illegal
Pharma industry middlemen are pushing back on a major drug price transparency proposal.
Stakeholders urge Labor Department to finalize PBM transparency rule
Employers, lawmakers and more said regulators should hustle to get disclosure mandates for the controversial drug middlemen across the finish line, while PBMs slammed the rule as illegal, unnecessary ...
STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
A deal with Regeneron was the last of 17 initially sought by the White House.